Lee Heeson Biography and Net Worth

EVP of Incyte

Lee Heeson joined Incyte in October of 2024 as Executive Vice President and Head of Incyte International. In his role, Mr. Heeson will lead commercial activities for Incyte outside of the United States, including Europe, Japan, Canada and rest of the world.

Prior to joining Incyte, Lee was Executive Vice President, Commercial International at Seagen; President of International at Vifor Pharma and President of Worldwide Markets at Celgene following other executive positions at the company. Earlier in his career, Lee held leadership positions at Galderma and Schering-Plough.

Lee holds a Bachelor of Arts, with honors, from Sheffield Hallam University.

What is Lee Heeson's net worth?: The estimated net worth of Lee Heeson is at least $2.79 million as of November 3rd, 2025. Heeson owns 29,241 shares of Incyte stock worth more than $2,789,884 as of December 14th. This net worth approximation does not reflect any other assets that Heeson may own. Learn More about Lee Heeson's net worth.
How do I contact Lee Heeson?: The corporate mailing address for Heeson and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Lee Heeson's contact information.
Has Lee Heeson been buying or selling shares of Incyte?: Over the course of the past ninety days, Lee Heeson has sold $289,017.48 of Incyte stock. Most recently, Lee Heeson sold 3,074 shares of the business's stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $94.02, for a transaction totalling $289,017.48. Following the completion of the sale, the executive vice president now directly owns 29,241 shares of the company's stock, valued at $2,749,238.82. Learn More on Lee Heeson's trading history.
Who are Incyte's active insiders?: Incyte's insider roster includes Sheila Denton (EVP), Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Lee Heeson (EVP), Herve Hoppenot (CEO & Chairman), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.
Are insiders buying or selling shares of Incyte?: During the last twelve months, insiders at the biopharmaceutical company sold shares 19 times. They sold a total of 130,466 shares worth more than $9,924,630.96. The most recent insider tranaction occured on December, 2nd when EVP Steven H Stein sold 20,105 shares worth more than $2,060,963.55. Insiders at Incyte own 17.8% of the company. Learn More about insider trades at Incyte.
Information on this page was last updated on 12/2/2025.

Lee Heeson Insider Trading History at Incyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/3/2025	Sell	3,074	$94.02	$289,017.48	29,241

Lee Heeson Buying and Selling Activity at Incyte

Incyte Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $95.41

$93.54

$96.00

50 Day Range

MA: $96.92

$83.80

$108.26

2 Week Range

Now: $95.41

$53.56

$109.28

Volume

2,213,736 shs

Average Volume

2,007,705 shs

Market Capitalization

$18.73 billion

P/E Ratio

15.98

Dividend Yield

N/A

Beta

0.81